Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Daratumumab [USAN:INN]
RN: 945721-28-8
UNII: 4Z63YK6E0E

Notes

  • An antineoplastic agent.
  • An antineoplastic agent.

    NCI: A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of daratumumab to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells. (NCI Thesaurus)
 

Classification Code

  • Antineoplastic Agents

Names and Synonyms

Name of Substance

  • Daratumumab [USAN:INN]

Synonyms

  • Anti-CD38 monoclonal antibody
  • Daratumumab
  • Darzalex
  • HuMax-CD38
  • JNJ 54767414
  • JNJ-54767414
  • UNII-4Z63YK6E0E

Registry Numbers

CAS Registry Number

  • 945721-28-8

FDA UNII

  • 4Z63YK6E0E

System Generated Number

  • 0945721288